Filing Flows › Bioadaptives (BDPT) › Q1 2026
Bioadaptives (BDPT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
Bioadaptives (BDPT) reported revenue of $6K for the first quarter 2026 (Q1 2026) and -47% from the quarter before.
Bioadaptives, Q1 2026: revenue $6K, net loss $111K, operating cash flow −$85K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6K | -47% | — |
| Operating profit | −$198K | — | — |
| Net earnings | −$111K | — | — |
| Operating cash flow | −$85K | — | — |
What changed
Revenue was $6K in Q1 2026, down 47% from the previous quarter.
Gross margin was 74.6%. Operating costs exceeded revenue by $198K, an operating margin of -3594.8%. The quarter ended with a net loss of $111K, narrower than the previous quarter's $823K loss. Non-operating items added $87K, -78% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$85K. Non-cash charges added back $2K of depreciation and amortization. Working capital and other items added $25K.
Questions
What was Bioadaptives' revenue in the first quarter 2026?
Bioadaptives (BDPT) reported revenue of $6K for the first quarter 2026 (Q1 2026) and -47% from the quarter before.
Source: Bioadaptives 10-Q on SEC EDGAR.